Trehalose eye drops in the treatment of dry eye syndrome

Toshihiko Matsuo, Yozo Tsuchida, Noriko Morimoto

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Objective: Trehalose can protect human corneal epithelial cells in culture from death from desiccation. This study was designed to test the efficacy and safety of trehalose eyedrops in the treatment of moderate to severe dry eye syndrome. Design: A randomized, double-masked, dose-ranging, fellow eye-controlled clinical trial. Participants: Thirty-four patients with moderate to severe dry eye syndrome. Methods: The patients used either 100 or 200 mM trehalose dissolved in saline six times daily in one eye and control saline in the other eye for 4 weeks. Main Outcome Measures: Symptoms and signs in both eyes were recorded separately at baseline, 2 weeks, and 4 weeks. Results: Fluorescein and rose bengal staining scores of the ocular surface improved at both 2 weeks and 4 weeks in the eyes with 100 and 200 mM trehalose, compared with eyes with control saline (P = 0.0030 to P <0.0001, respectively, Mann-Whitney U test). Tear film breakup time became significantly longer at 2 weeks and 4 weeks with 100 mM trehalose (P = 0.0024 and P <0.0001, respectively), but not with 200 mM trehalose. No adverse effect attributable to trehalose solution was noted. Conclusions: Trehalose solution was an effective and safe eyedrop for the treatment of moderate to severe dry eye syndrome in this group of patients.

Original languageEnglish
Pages (from-to)2024-2029
Number of pages6
JournalOphthalmology
Volume109
Issue number11
DOIs
Publication statusPublished - Nov 1 2002

Fingerprint

Dry Eye Syndromes
Trehalose
Ophthalmic Solutions
Therapeutics
Rose Bengal
Desiccation
Controlled Clinical Trials
Nonparametric Statistics
Fluorescein
Tears
Signs and Symptoms
Cell Culture Techniques
Epithelial Cells
Outcome Assessment (Health Care)
Staining and Labeling
Safety

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Trehalose eye drops in the treatment of dry eye syndrome. / Matsuo, Toshihiko; Tsuchida, Yozo; Morimoto, Noriko.

In: Ophthalmology, Vol. 109, No. 11, 01.11.2002, p. 2024-2029.

Research output: Contribution to journalArticle

Matsuo, Toshihiko ; Tsuchida, Yozo ; Morimoto, Noriko. / Trehalose eye drops in the treatment of dry eye syndrome. In: Ophthalmology. 2002 ; Vol. 109, No. 11. pp. 2024-2029.
@article{7bb04837b2c24ca18694b3768e37a027,
title = "Trehalose eye drops in the treatment of dry eye syndrome",
abstract = "Objective: Trehalose can protect human corneal epithelial cells in culture from death from desiccation. This study was designed to test the efficacy and safety of trehalose eyedrops in the treatment of moderate to severe dry eye syndrome. Design: A randomized, double-masked, dose-ranging, fellow eye-controlled clinical trial. Participants: Thirty-four patients with moderate to severe dry eye syndrome. Methods: The patients used either 100 or 200 mM trehalose dissolved in saline six times daily in one eye and control saline in the other eye for 4 weeks. Main Outcome Measures: Symptoms and signs in both eyes were recorded separately at baseline, 2 weeks, and 4 weeks. Results: Fluorescein and rose bengal staining scores of the ocular surface improved at both 2 weeks and 4 weeks in the eyes with 100 and 200 mM trehalose, compared with eyes with control saline (P = 0.0030 to P <0.0001, respectively, Mann-Whitney U test). Tear film breakup time became significantly longer at 2 weeks and 4 weeks with 100 mM trehalose (P = 0.0024 and P <0.0001, respectively), but not with 200 mM trehalose. No adverse effect attributable to trehalose solution was noted. Conclusions: Trehalose solution was an effective and safe eyedrop for the treatment of moderate to severe dry eye syndrome in this group of patients.",
author = "Toshihiko Matsuo and Yozo Tsuchida and Noriko Morimoto",
year = "2002",
month = "11",
day = "1",
doi = "10.1016/S0161-6420(02)01219-8",
language = "English",
volume = "109",
pages = "2024--2029",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",
number = "11",

}

TY - JOUR

T1 - Trehalose eye drops in the treatment of dry eye syndrome

AU - Matsuo, Toshihiko

AU - Tsuchida, Yozo

AU - Morimoto, Noriko

PY - 2002/11/1

Y1 - 2002/11/1

N2 - Objective: Trehalose can protect human corneal epithelial cells in culture from death from desiccation. This study was designed to test the efficacy and safety of trehalose eyedrops in the treatment of moderate to severe dry eye syndrome. Design: A randomized, double-masked, dose-ranging, fellow eye-controlled clinical trial. Participants: Thirty-four patients with moderate to severe dry eye syndrome. Methods: The patients used either 100 or 200 mM trehalose dissolved in saline six times daily in one eye and control saline in the other eye for 4 weeks. Main Outcome Measures: Symptoms and signs in both eyes were recorded separately at baseline, 2 weeks, and 4 weeks. Results: Fluorescein and rose bengal staining scores of the ocular surface improved at both 2 weeks and 4 weeks in the eyes with 100 and 200 mM trehalose, compared with eyes with control saline (P = 0.0030 to P <0.0001, respectively, Mann-Whitney U test). Tear film breakup time became significantly longer at 2 weeks and 4 weeks with 100 mM trehalose (P = 0.0024 and P <0.0001, respectively), but not with 200 mM trehalose. No adverse effect attributable to trehalose solution was noted. Conclusions: Trehalose solution was an effective and safe eyedrop for the treatment of moderate to severe dry eye syndrome in this group of patients.

AB - Objective: Trehalose can protect human corneal epithelial cells in culture from death from desiccation. This study was designed to test the efficacy and safety of trehalose eyedrops in the treatment of moderate to severe dry eye syndrome. Design: A randomized, double-masked, dose-ranging, fellow eye-controlled clinical trial. Participants: Thirty-four patients with moderate to severe dry eye syndrome. Methods: The patients used either 100 or 200 mM trehalose dissolved in saline six times daily in one eye and control saline in the other eye for 4 weeks. Main Outcome Measures: Symptoms and signs in both eyes were recorded separately at baseline, 2 weeks, and 4 weeks. Results: Fluorescein and rose bengal staining scores of the ocular surface improved at both 2 weeks and 4 weeks in the eyes with 100 and 200 mM trehalose, compared with eyes with control saline (P = 0.0030 to P <0.0001, respectively, Mann-Whitney U test). Tear film breakup time became significantly longer at 2 weeks and 4 weeks with 100 mM trehalose (P = 0.0024 and P <0.0001, respectively), but not with 200 mM trehalose. No adverse effect attributable to trehalose solution was noted. Conclusions: Trehalose solution was an effective and safe eyedrop for the treatment of moderate to severe dry eye syndrome in this group of patients.

UR - http://www.scopus.com/inward/record.url?scp=0036840567&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036840567&partnerID=8YFLogxK

U2 - 10.1016/S0161-6420(02)01219-8

DO - 10.1016/S0161-6420(02)01219-8

M3 - Article

C2 - 12414409

AN - SCOPUS:0036840567

VL - 109

SP - 2024

EP - 2029

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

IS - 11

ER -